NEW YORK, NY / ACCESSWIRE / March 6, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cypress Semiconductor Corporation ("Cypress" or "the Company") (NASDAQ:CY). Investors who purchased Cypress securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cy.
The investigation concerns whether Cypress and certain of its officers and/or directors have violated federal securities laws.
On March 3, 2020, the Food and Drug Administration ("FDA") issued a news release "informing patients, health care providers and manufacturers about a set of cybersecurity vulnerabilities, referred to as ‘SweynTooth,' that-if exploited-may introduce risks for certain medical devices." The FDA named Cypress as one "of several manufacturers that are affected by these vulnerabilities." On this news, Cypress's stock price fell sharply over the following trading sessions.
If you are aware of any facts relating to this investigation or purchased Cypress shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC